Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 (Q24657145)

2

0 references

R D Gelber

3

0 references

A S Coates

4

0 references

B Thürlimann

5

0 references

H-J Senn

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

6

0 references

language of work or name

English

0 references

publication date

August 2009

0 references

1 August 2009

3 references

13 March 2019

3 April 2019

17 June 2019

3 references

13 March 2019

3 April 2019

17 June 2019

20

0 references

issue

8

0 references

page(s)

1319-29

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

A gene-expression signature as a predictor of survival in breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Endogenous human microRNAs that suppress breast cancer metastasis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

EGF-ERBB signalling: towards the systems level

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Molecular imaging of breast cancer.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Gene-expression signatures in breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Breast cancer after use of estrogen plus progestin in postmenopausal women

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

PET imaging of steroid receptor expression in breast and prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Unique ERalpha cistromes control cell type-specific gene regulation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Survival and prognostic factors in BRCA1-associated breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

The biological information obtainable from circulating tumor cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

30 May 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Virtual and biomolecular screening converge on a selective agonist for GPR30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP322

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720818

Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy

28 November 2018

1 reference

12 December 2020

Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up

1 reference

12 December 2020

Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions

1 reference

12 December 2020

The follow-up of women at high risk for breast cancer relapse

1 reference

12 December 2020

TAILORx: trial assigning individualized options for treatment (Rx)

1 reference

12 December 2020

Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?

1 reference

12 December 2020

Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer

1 reference

12 December 2020

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

12 December 2020

Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index

1 reference

12 December 2020

Identifiers

DOI

10.1093/ANNONC/MDP322

1 reference

208643

208643

1 reference

1 reference

1 reference